Cyclerion Therapeutics (CYCN) Operating Margin (2019 - 2025)
Cyclerion Therapeutics (CYCN) recorded quarterly Operating Margin of 114.97% in Q3 2025, up 93.61% quarter-over-quarter from 1797.85% in Q2 2025, and up 46647.0% on a YoY basis from N/an in Q3 2024.
Cyclerion Therapeutics (CYCN) Operating Margin (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics' Operating Margin history runs 6 years deep, the most recent figure standing at 114.97% for Q3 2025.
- In Q3 2025, Operating Margin rose 46647.0% year-over-year to 114.97%; the TTM figure through Sep 2025 stood at 127.25% (up 292687.0% YoY), while the FY2024 annual figure was 181.4%, changed N/A from the prior year.
- Operating Margin was 114.97% for Q3 2025 at Cyclerion Therapeutics, up from 1797.85% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 27.8% in Q4 2024 to a low of 21604.84% in Q1 2021.
- Historically, Operating Margin has averaged 3505.29% across 4 years, with a median of 1798.77% in 2025.
- The sharpest annual moves came in 2021 and 2022: Operating Margin plunged 1957437 bps in 2021, then jumped 1977868 bps in 2022.
- A 4-year view of Operating Margin shows it stood at 2690.06% in 2021, then tumbled by 63 bps to 4389.87% in 2022, then soared by 101 bps to 27.8% in 2024, then tumbled by 514 bps to 114.97% in 2025.
- The last three Operating Margin figures came in at 114.97% (Q3 2025), 1797.85% (Q2 2025), and 1798.77% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Cyclerion Therapeutics | 11.50 Mn | 8.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -114.97% |
| Jun 30, 2025 | -1,797.85% |
| Mar 31, 2025 | -1,798.77% |
| Dec 31, 2024 | 27.80% |
| Sep 30, 2024 | -581.44% |
| Jun 30, 2022 | -4,389.87% |
| Mar 31, 2022 | -1,826.16% |
| Dec 31, 2021 | -2,690.06% |
| Sep 30, 2021 | -3,242.82% |
| Jun 30, 2021 | -539.20% |
| Mar 31, 2021 | -21,604.84% |
| Dec 31, 2020 | -14,454.14% |
| Sep 30, 2020 | -5,445.00% |
| Jun 30, 2020 | -2,626.44% |
| Mar 31, 2020 | -2,030.47% |
| Dec 31, 2019 | -1,795.14% |
| Sep 30, 2019 | -2,004.01% |
| Jun 30, 2019 | -2,030.34% |